University at Buffalo - The State University of New York
Skip to Content
Uriel                          Halbreich

Uriel Halbreich MD

Department of Psychiatry

Professor and Director, BioBehavioral Research

Specialty/Research Focus

Behavioral pharmacology; Endocrinology; Endocrinology, Diabetes and Metabolism; Neurobiology; Psychiatry

 
Professional Summary:

My research is broadly concerned with studies of the biology of affective disorders and the development of biological markers and clinical laboratory tests for major depressive disorder. Hormonal modulation of brain and behavior with the emphasis on gonadal hormones and the hypothalamic-pituitary-adrenal system neurotransmitter and their metabolites.

A second area of work involves studies of premenstrual changes and menopause and hormone related changes in mood and behavior in women. Studies include: influence of hormonal replacement therapy; the development of clinical and diagnostic procedures; the association between gonadal hormones and other hormones, their change over time and clinical pathology, and the relationship between affective symptomatology during periods of change in the woman‘s life cycle and affective disorders.

Education and Training:
  • Fellowship, Columbia University (1980)
  • Psychiatric Ward (Continuation of Training), Hadassah University Hospital (1978)
  • Dipl, Tel Aviv University, Sakler Postgraduate Medical School (1978)
  • Liaison Psychiatry (Continuation of Training), Kaplan Hospital, Outpatient Clinic (1976)
  • Community Psychiatry (Continuation of Training), Jerusalem Community Mental Health Center (1976)
  • Neurology (Continuation of Training), Hadassah University Hospital (1976)
  • Residency, Talbieh Psychiatric Hospital (1974)
  • MD, University Hadassah Medical School (1969)
  • Medical Officer's Course, Israeli Army (1969)
  • Internship, Medicine, Hadassah University Hospital (1968)
  • Student, University Hadassah Medical School (1961)
Employment:
  • Teaching Professor of OB/GYN, OB/GYN, University of Pisa (2007-present)
  • Consultant, Kaleida Healthcare Systems (1998-present)
  • Research Professor of Ob/Gyn, State University of New York at Buffalo (1988-present)
  • Founder and Director of the Life Cycle Center, psychosomatic Ob/Gyn Division, State University of New York at Buffalo (1987-present)
  • Professor of Psychiatry, State University of New York at Buffalo (1985-present)
  • Director of Bio-behavioral Research, Psychiatry, State University of New York at Buffalo (1985-present)
  • Attending Physician, Erie County Medical Center (1985–2007)
  • Executive Consultant, Psychiatry, Harvard University Medical School (1998–2001)
  • Visiting Professor, Harvard University, Medical School (1996–1998)
  • Consultant, Buffalo VA Medical Center (1985–1996)
  • Founder and Director, Affective Disorders Program, SUNY/AB at Erie County Medical Center (1986–1993)
  • Consultant, Buffalo Psychiatric Center (1987–1992)
  • Founder and Director, Affective Disorders Clinic, Albert Einstein College of Medicine (1984–1985)
  • Associate Professor of Psychiatry, Psychiatry, AECOM (1982–1985)
  • Research Associate, Montefiore Hospital and Medical Center (1980–1985)
  • Founder and Director, Division of Biological Psychiatry, Albert Einstein College of Medicine (1982–1984)
  • Director, Division of Behavioral Endocrinology, Albert Einstein College of Medicine (1980–1982)
  • Assistant Professor of Psychiatry, Psychiatry, AECOM (1980–1982)
  • Assistant Professor of Clinical Psychiatry, Psychiatry, Columbia University, College of Physicians and Surgeons (1978–1980)
  • Research Psychiatrist, New York State Psychiatric Institute (1978–1980)
  • Temporary Chief Physician, Psychiatry, Hadassah University Hospital, Israel (1978)
  • Lecturer of Psychiatry, Psychiatry, Hebrew University Hadassah Medical School, Israel (1977–1978)
  • Chief Psychiatrist, Israeli Navy (Active Reserve), Israel (1977–1978)
  • Lecturer, Bezalel Academy of Arts, Israel (1976–1978)
  • First Assistant, Psychiatry, Hadassah University Hospital, Israel (1976–1978)
  • Second Assistant, Psychiatry, Kaplan Hospital, Israel (1974–1976)
  • Vice Chief Medical Officer, Israeli Navy, Israel (1970–1972)
  • Regiment Medical Officer, Israeli Army, Israel (1969–1970)
See all (18 more)
Awards and Honors:
  • Honorary Fellow (2008)
  • America's Top Psychiatrist (2008)
  • Service Award (2003)
  • Citations in National and International Who's Who (1984)
  • National Research Service Award (1980)
  • Yon Gon Award (1978)
  • Ben Gurion Award (1976)

Grants and Sponsored Research:
  • January 2005–January 2008
    A multicenter, randomized, double-blind, placebo- controlled study of the safety and efficacy of Arpiprazole as adjunctive therapy in the treatment of patients with major depressive disorder
    Bristol Myers Squibb Co.
    Role: Co-Investigator
  • January 2004–January 2008
    Olanzapine vs. Aripiprazole in the treatment of acutely ill patients with schizophrenia
    Eli Lilly and Company
    Role: Co-Investigator
  • January 2002–January 2008
    Identification and diagnosis of mental disorders in Beijing Ob/Gyn clinics
    Pfizer Inc. Foundation
    Role: Co-Investigator
  • January 2005–January 2007
    A randomized, double-blind, placebo-controlled, parallel group study of the safety and efficacy of three dose levels of CORLUX (Mifepristone) plus an antidepressant vs. placebo plus and antidepressant in the treatment of psychotic symptoms in patients wi
    Corcept
    Role: Co-Investigator
  • January 2005–January 2007
    Diagnosis of clinically relevant premenstrual syndromes- Achieving international interdisciplinary consensus for update of ICD-10 Diagnosis of PMS
    Schering Inc.
    Role: Co-Investigator
  • January 2002–January 2003
    Phase III, open label, multicenter, multinational, contraceptive study of Medroxyprogesterone Acetate (MPA: mg) and Estradiol Cypionate (E2C 5 mg) injectable suspension administered subcutaneously
    Pharmacia
    Role: Co-Investigator
  • January 2001–January 2003
    The Relationship between Valproate and Other Mood-Stabilizer Therapies to the Polycystic Ovarian Syndrome and Polycystic Ovarian Morphology in Women with Bipolar Disorder
    Harvard Medical School
    Role: Co-Investigator
  • January 1999–January 2003
    Beijing Double Blind Placebo Controlled Trial Comparing Fluoxetine to Electro-Acupuncture
    Eli Lilly and Company
    Role: Co-Investigator
  • January 1999–January 2003
    A Comparative Study of the Steady-State Pharmacokinetics of Lithium Before and During Multiple Oral Daily Topiramate Dosing in patients with Bipolar Disorder
    R.W. Johnson
    Role: Co-Investigator
  • January 2001–January 2002
    Systemic Treatment Enhancement Program for Bipolar Disorder
    Role: Principal Investigator
  • January 2001–January 2002
    Phase IIIB Multi center trial, a comparison of Lunelle and Depo-Provera on Bone Mineral Density
    Pharmacia
    Role: Co-Investigator
  • January 2000–January 2002
    A randomized, placebo-controlled, double blind study of Naltrel in promotion of abstinence among alcohol dependent subjects
    Drug Abuse Science
    Role: Co-Investigator
  • January 1999–January 2002
    Risperidone Depot (Microspheres) in the treatment of Subjects with Schizophrenia and Schizoaffective Disorder
    Janssen
    Role: Co-Investigator
  • January 1999–January 2002
    Systematic Treatment Enhancement Program for Bipolar Disorder
    National Institute of Mental Health
    Role: Principal Investigator
  • January 1998–January 2002
    A double blind, randomized, placebo and historical controlled study of the safety and efficacy of premarin/trimegestrone for post menopausal hormone replacement therapy
    Wyeth Ayerst Research
    Role: Co-Investigator
  • January 1999–January 2001
    Olanzapine Alone & in Combination with Fluoxetine vs. Placebo in Major Depressive Disorder with Psychotic Features
    Eli Lilly and Company
    Role: Co-Investigator
  • January 1999–January 2001
    Study of St. John's Wart on Outpatients with DSM-IV Major Depression
    Vanderbilt Research University
    Role: Co-Investigator
  • January 1998–January 2001
    Intermittent Dosing of Fluoxetine in the Treatment of Premenstrual Dysphoric Disorder: Late Luteal Phase Daily Dosing Versus Placebo
    Eli Lilly and Company
    Role: Co-Investigator
  • January 1999–January 2000
    Reboxetine vs. Placebo in the treatment of Major Depressive Disorder Resistant to Fluoxetine
    Pharmacia Upjohn
    Role: Co-Investigator
  • January 1999–January 2000
    Pharmacogenomics Blood Sampling Protocol
    Pharmacia Upjohn
    Role: Co-Investigator
  • January 1999–January 2000
    Open Label Reboxetine Rescue and Continuation Therapy
    Pharmacia Upjohn
    Role: Co-Investigator
  • January 1998–January 2000
    Olanzapine in the Reduction of Hyperprolactinemia
    Eli Lilly and Company
    Role: Co-Investigator
  • January 1996–January 2000
    Double-Blinded Parallel Comparison of Luteal Phase Treatment with Sertraline and Placebo in Patients with Premenstrual Dysphoric Disorder
    Pfizer, Inc.
    Role: Co-Investigator
  • January 1997–January 1998
    Reboxetine versus Placebo in the treatment of Major Depressive Disorder
    Pharmacia Upjohn
    Role: Co-Investigator
  • January 1996–January 1998
    A Ten-Week, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of Oral CP-93,393-1 in outpatients with Major Depressive Disorder
    Role: Co-Investigator
  • January 1993–January 1997
    Treatment of dysphoric menstrual syndromes with mifepristone (RU-486)
    Rousel Uclaf
    Role: Co-Investigator
  • January 1995–January 1996
    Fifty -two week, open label, randomized study evaluating the safety and efficacy of oral ziprasidone (CP-88-059-1) 40-80 mg, bid and risperidone (3-5 mg daily) in the maintenance treatment of outpatients with schizophrenia or schizo-affective disorder
    Role: Co-Investigator
  • January 1995–January 1996
    Intermittent late luteal treatment with sertraline of women with dysphoric PMS-- A Pilot Study
    Role: Co-Investigator
  • January 1994–January 1996
    Sertraline (Placebo controlled, double blind) for treatment of women with dysphoric premenstrual syndrome
    Pfizer Inc., U.S. Pharmaceutical Group
    Role: Co-Investigator
  • September 1991–August 1995
    Alpha 2 Receptors, Luteal Depression and Gonadal Hormones
    National Institute of Mental Health
    Role: Principal Investigator
    $518,074
  • June 1990–April 1994
    Menstrually Related Changes in Cognitive Functions
    National Institute of Mental Health
    Role: Principal Investigator
    $101,869
  • January 1994–January 1994
    Welbutrin sustained release form, as treatment for major depressive disorders
    Burroughs Wellcome Co.
    Role: Co-Investigator
  • January 1994–January 1994
    Assessment of Mood and Cognition in Woman with Breast Cancer
    Nathan Cummings Foundation
    Role: Co-Investigator
  • January 1993–January 1994
    Double blind follow-up comparison of sertraline, imipramine and placebo in patients with dysthymic disorder
    Pfizer Inc., U.S. Pharmaceutical Group
    Role: Co-Investigator
  • January 1992–January 1993
    Luproid acetate depot for treatment of dysphoric PMS
    TAP Pharmaceuticals, Inc.
    Role: Co-Investigator
  • January 1992–January 1993
    Double blind parallel comparison of sertraline, imipramine and placebo in outpatients with Dysthymia
    Pfizer Inc., U.S. Pharmaceutical Group
    Role: Co-Investigator
  • January 1991–January 1993
    Estraderm patches as treatment of dysphoric PMS, an their influence on cognitive functions and the Imidazoline- CDS system
    Ciba Geigi Co.
    Role: Co-Investigator
  • January 1992–January 1992
    Abecarnil (Placebo Controlled, low and high dose) for treatment of outpatients with Generalized Anxiety disorder
    Sandoz Pharmaceuticals Corp.
    Role: Co-Investigator
  • January 1991–January 1991
    Drug Induced Osteoporosis and Behavioral Changes
    Research for Health in Erie County
    Role: Co-Investigator
  • January 1990–January 1991
    Hormonal Modulation of Brain and Behavior
    RGK Foundation
    Role: Co-Investigator
  • January 1989–January 1990
    Hormonal Modulation of Brain and Behavior
    Daniel Roblins Memorial Fund
    Role: Co-Investigator
  • January 1989–January 1989
    The Use of Hydrochlorothiazide for Premenstrual Edema
    Bristol Myers Squibb Co.
    Role: Co-Investigator
  • January 1987–January 1989
    Administrative Structure for Brain & Behavioral Research
    National Institute of Mental Heath
    Role: Principal Investigator
  • January 1985–January 1989
    The Desipramine Cortisol Test in Depression
    National Institute of Mental Health
    Role: Co-Investigator
  • January 1987–January 1988
    Clinical Study of Bupropion in Depression
    Burroughs Wellcome Co.
    Role: Co-Investigator
  • January 1985–January 1988
    Biological Studies of Depression
    SUNY- Biomedical Research
    Role: Principal Investigator
  • January 1987–January 1987
    Biology of Aberrant Behavior
    Bernice P. Roger's Trust
    Role: Co-Investigator
  • January 1985–January 1987
    Cortisol, MHPG and Depression
    National Institute of Mental Health
    Role: Principal Investigator
  • January 1981–January 1986
    Premenstrual Syndromes: Biological and Diagnostic
    National Institute of Mental Health
    Role: Co-Principal Investigator
  • January 1985–January 1985
    Preliminary Studies of Tardive Dyskinesia
    The Ritter's Foundation
    Role: Co-Investigator
  • January 1982–January 1985
    Cortisol Secretion and Depression: A New Test
    National Institute of Mental Health
    Role: Principal Investigator
  • January 1983–January 1984
    The Prolactin Response to Reserpine in Schizophrenia
    National Institute of Mental Health
    Role: Co-Investigator
  • January 1983–January 1984
    Biology of Affective Disorders and Schizophrenia
    The Ritter's Foundation
    Role: Co-Investigator
  • January 1982–January 1982
    Research in Biological Psychiatry
    Richard Hirschfeld‘s Bequest
    Role: Co-Investigator
    $248,000
  • January 1982–January 1982
    The Dean's Discretionary Fund
    Richard Hirschfeld‘s Bequest
    Role: Co-Investigator
    $164,000
  • January 1982–January 1982
    Biology of Affective Disorders and Premenstrual Changes
    The Ritter's Foundation
    Role: Co-Investigator
  • January 1980–January 1981
    Endocrinology of Mental Disorders
    SUNY- Biomedical Research Grant
    Role: Principal Investigator
  • January 2005
    A multicenter, randomized, double-blind, placebo- controlled study of a combination of levonorgestrel and ethinyl estradiol in a continuous daily regimen in subjects with premenstrual dysphoric disorder
    Wyeth Ayerst Research
    Role: Co-Investigator
  • January 1994
    2nd International Congress of Women's Mental Health
    2nd International Congress of Women's Mental Health
    Role: Co-Investigator
    $811,170
  • Prevalence of Hyperprolactinemia in Schizophrenic Patients Treated with Antipsychotic Drugs
    Eli Lilly and Company
    Role: Co-Investigator
See all (50 more)

Journal Articles:
See all (143 more)
Evaluative Studies and Case Reports:

Service Activities:
  • Jacobs School of Medicine & Biomedical Sciences Admissions Committee; Member (2004–2006)
  • Faculty Senate; Member (2002–2004)
  • Psychiatry, Jacobs School of Medicine & Biomedical Sciences Department of Psychiatry Continuing Medical Education; Member (1998)
  • Jacobs School of Medicine & Biomedical Sciences Apppointment, Promotions,Tenure & Privileges; Member (1990–1994)
  • Jacobs School of Medicine & Biomedical Sciences Faculty Council; Member (1989–1992)
  • Jacobs School of Medicine & Biomedical Sciences Faculty Council; Member (1986–1987)
  • Psychiatry, Jacobs School of Medicine & Biomedical Sciences Department of Psychiatry Continuing Medical Education; Member (1985–1996)
  • Psychiatry, Jacobs School of Medicine & Biomedical Sciences Department of Psychiatry Research Committee; Chair (1985–1993)
  • Psychiatry, Jacobs School of Medicine & Biomedical Sciences Department of Psychiatry Appointments, Promotions, and Tenure Comittee; Member (1985–1990)
  • H&J Med Infor Consultants; President (2006–present)
  • IN-CLINE RE&D; President (2006–present)
  • Buffalo West Side and Buffalo East Side Task Forces; Member (2005–present)
  • International Society of Affective Disorders; Member (2004–2006)
  • World Psychiatric Association; Section on Affective Disorders; Co-Chair (2004–2005)
  • World Innovation Foundation (2002)
  • American Psychiatric Association; Committee on Research on psychiatric Treatements- 2006- Present (2002–present)
  • International Society of PsychoNeuroEndocrinology; President (2002–present)
  • World Innovation Foundation (2002–present)
  • International Association for Women's Mental Health; President (2001–2004)
  • International Association for Women‘s Mental Health (2001–2004)
  • International Association for Women's Mental Health; Member (2001–present)
  • 2nd HBN Congress; Chairman (2000)
  • International Society of PsychoNeuroEndocrinology; President (1999–2002)
  • International Society of PsychoNeuroEndocrinology; President (1999–2002)
  • American Psychiatric Society (1999)
  • International Brain Research Organization; Member (1999–present)
  • Executive Committee and Board of Directors; Jewish Family Services; Member (1998–2005)
  • American College of Physician Executives; Member (1998–2002)
  • American College of Forensic Examiners (1998–2001)
  • World Psychiatric Association; Section on Interdisciplinary Collaboration; Chairman (1997–present)
  • World Psychiatric Association section on Interdisciplinary Collaboration; Chairman (1997–present)
  • Hormones, Brain and Neuropsychopharmacology (HBN); President (1993–2005)
  • 1st International Congress on Hormones, Brain and NeuroPsychoPharmacology; Chairman (1993)
  • Association of Medicine and Psychiatry; Member (1991–2000)
  • XXI Congress of the International Society of PsychoNeuroEndocrinology; Chairman (1990)
  • Collegium Internationale Neuropsychopharmacologicum; Education Committee, 1989-1996, 2002- Present Co-Chair- Education Committee, 1994-1996 Awards and Fellowship Committee, 1998-2000; Member (1989–2002)
  • Task Force for Psychiatric Clinical Services; Medical Consortium Erie County; Member (1989–1990)
  • Society of Neuroscience; Member (1988–2005)
  • American Neuropsychiatric Society; Member (1988–2003)
  • American Neuropsychiatric Society; Member (1988–2003)
  • Task Force for Ob/Gyn Clinical Services; Medical Consortium Erie County; Member (1988–1989)
  • American College of Psychiatrists; Program Committee- 1991-1995 Scientific Program Committee- 1999-2002; Member (1987–2002)
  • American Society for Psychosomatic Obstetrics and Gynecology; Member (1987–1994)
  • World Federation for Mental Health; Member (1986–present)
  • American College of NeuroPsychopharmacology; Education and Training Committee, 1985-1988 Program and Scientific Communication Committee, 1988-1991 CME Liaison, 1992-1993 Constitution and Rules Committee, 1994-1996 Chairman, Constitution and Rules Committee 1996; Member (1985–2000)
  • American Psychiatric Association (1983–present)
  • American Association for the Advancement of Science; Member (1982–2002)
  • New York Academy of Science; Member (1982–2000)
  • Society of Biological Psychiatry; Member (1982–1993)
  • American Psycho-Pathology Association (1982–present)
  • International Society of PsychoNeuroEndocrinology; Member (1982–present)
  • The Endocrine Society; Member (1980–2005)
  • American Federation for Clinical Research; Member (1980–1989)
  • American Society of Psychopathology of Expression; Member (1980–1984)

School News:
In the Media:

Clinical Specialties:
Clinical Offices:
Insurance Accepted:


Contact Information

255 Nottingham Terrance
Buffalo, NY 14216
Phone: 716-875-4989
Email: urielh@buffalo.edu

Patient Care

Looking for a doctor? This faculty member is affiliated with UBMD, the group comprised of practicing physicians who are also professors in the UB Jacobs School of Medicine and Biomedical Sciences.

View this faculty on UBMD

Log in to Update Your Profile